Status:
COMPLETED
Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Canceropôle Nord Ouest
Saint-Louis Hospital, Paris, France
Conditions:
Acute Myeloid Leukemia
Eligibility:
FEMALE
2-40 years
Brief Summary
Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation. This pilot stu...
Eligibility Criteria
Inclusion
- Patient diagnosed with AML
- At least one molecular marker identified at AML diagnosis
- Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation.
Exclusion
- Other diagnostic
- No marker available at AML diagnosis
- No bone marrow/ovarian fragment available at the time of complete remission
Key Trial Info
Start Date :
April 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 4 2022
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04679285
Start Date
April 26 2021
End Date
September 4 2022
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU lille
Lille, France, 59037